Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:4947 |
| Name | cholangiocarcinoma |
| Definition | A bile duct adenocarcinoma that has_material_basis_in bile duct epithelial cells. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:5249 |
| Xrefs |
ICDO:8160/3
SNOMEDCT_US_2023_03_01:70179006
|
| Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer biliary tract cancer bile duct cancer bile duct carcinoma bile duct adenocarcinoma cholangiocarcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF V600X | Vemurafenib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 fusion | Infigratinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 mutant | Infigratinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 fusion FGFR2 V564F | Infigratinib | cholangiocarcinoma | predicted - resistant | detail... |
| IDH1 mutant | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 fusion | Futibatinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 rearrange | Futibatinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 rearrange FGFR2 amp | Futibatinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 rearrange | Pemigatinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 mutant | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR3 mutant | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 fusion | Erdafitinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 fusion | Pemigatinib | cholangiocarcinoma | sensitive | detail... |
| BRAF V600E | Vemurafenib | cholangiocarcinoma | predicted - sensitive | detail... |
| IDH1 R132C | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
| IDH1 R132S | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
| IDH1 R132L | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
| IDH1 R132G | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
| FGFR3 amp | Infigratinib | cholangiocarcinoma | no benefit | detail... |
| FGFR2 amp | Infigratinib | cholangiocarcinoma | sensitive | detail... |
| BRAF V600E | Dabrafenib + Trametinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 fusion | ICP-192 | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 rearrange | Infigratinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 M537I FGFR2 V564L FGFR2 amp | Infigratinib | cholangiocarcinoma | predicted - resistant | detail... |
| IDH1 R132H | Ivosidenib | cholangiocarcinoma | sensitive | detail... |
| IDH1 R132S | Ceralasertib + Olaparib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 C382R | Pemigatinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 fusion | Lirafugratinib | cholangiocarcinoma | predicted - sensitive | detail... |
| RET fusion | Selpercatinib | cholangiocarcinoma | sensitive | detail... |
| BRAF V600E | Cobimetinib + Vemurafenib | cholangiocarcinoma | predicted - sensitive | detail... |
| IDH1 R132C | Olaparib | cholangiocarcinoma | no benefit | detail... |
| IDH1 R132C | Pamiparib | cholangiocarcinoma | no benefit | detail... |
| IDH1 R132C | Niraparib | cholangiocarcinoma | no benefit | detail... |
| ARID1A A35Gfs*76 | Olaparib | cholangiocarcinoma | no benefit | detail... |
| ARID1A A35Gfs*76 | Pamiparib | cholangiocarcinoma | no benefit | detail... |
| ARID1A A35Gfs*76 | Niraparib | cholangiocarcinoma | no benefit | detail... |
| FGFR2 I291_Y308del | Pemigatinib | cholangiocarcinoma | predicted - sensitive | detail... |
| BRAF V600E | BGB3245 | cholangiocarcinoma | predicted - sensitive | detail... |
| IDH1 act mut | LY3410738 | cholangiocarcinoma | predicted - sensitive | detail... |
| IDH2 act mut | LY3410738 | cholangiocarcinoma | predicted - sensitive | detail... |
| IDH1 mutant | Durvalumab + Olaparib | cholangiocarcinoma | no benefit | detail... |
| FGFR2 C382R | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 act mut | Tinengotinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 Y375C | Futibatinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 H167_N173del | Infigratinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 N631_M640del | Infigratinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 I548Wfs*8 | Infigratinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 I288_D304del | Infigratinib | cholangiocarcinoma | no benefit | detail... |
| FGFR2 C382R | Infigratinib | cholangiocarcinoma | no benefit | detail... |
| FGFR2 K545del | Infigratinib | cholangiocarcinoma | no benefit | detail... |
| FGFR2 S372C | Lenvatinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 fusion | E7090 | cholangiocarcinoma | predicted - sensitive | detail... |
| MLH1 negative | Nivolumab | cholangiocarcinoma | predicted - sensitive | detail... |
| MSH2 negative | Nivolumab | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 C382R | Tinengotinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 I291_Y308del FGFR2 N549K | Pemigatinib | cholangiocarcinoma | predicted - resistant | detail... |
| FGFR2 C382R FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564L | Pemigatinib | cholangiocarcinoma | predicted - resistant | detail... |
| ATM G1676fs | Talazoparib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR1 rearrange | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 rearrange | Erdafitinib | cholangiocarcinoma | sensitive | detail... |
| FGFR3 rearrange | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 fusion | Gemcitabine + Pemigatinib | cholangiocarcinoma | sensitive | detail... |
| FGFR2 C383R | Erdafitinib | cholangiocarcinoma | predicted - sensitive | detail... |
| FGFR2 C383R FGFR2 N550D FGFR2 N550K FGFR2 V565L | Erdafitinib | cholangiocarcinoma | predicted - resistant | detail... |
| FGFR2 rearrange FGFR2 N550D FGFR2 N550H FGFR2 N550K FGFR2 N550T FGFR2 V565I FGFR2 V565L | Pemigatinib | cholangiocarcinoma | predicted - resistant | detail... |
| FGFR2 L262_A266delinsD NRAS Q61K | Futibatinib | cholangiocarcinoma | predicted - resistant | detail... |
| FGFR2 rearrange NRAS Q61K | Pemigatinib | cholangiocarcinoma | predicted - resistant | detail... |
| FGFR2 F276C | Pemigatinib | cholangiocarcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
| NCT01438554 | Phase I | Pazopanib + Trametinib | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | USA | 0 |
| NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
| NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | GBR | FRA | ESP | DNK | DEU | 0 |
| NCT01825603 | Phase I | ADH-1 + Cisplatin + Gemcitabine | ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery | Completed | USA | 0 |
| NCT01888302 | Phase I | Cisplatin + Gemcitabine + Sirolimus | Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery | Completed | USA | 0 |
| NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
| NCT02052778 | Phase Ib/II | Futibatinib | A Study of TAS-120 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 4 |
| NCT02053376 | Phase II | Regorafenib | A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy | Completed | USA | 0 |
| NCT02128282 | Phase Ib/II | Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Silmitasertib | Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | Completed | USA | 2 |
| NCT02150967 | Phase II | Infigratinib | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Terminated | USA | ITA | GBR | ESP | DEU | BEL | 5 |
| NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
| NCT02232633 | Phase II | Amcasertib | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | Completed | CAN | 0 |
| NCT02240238 | Phase Ib/II | Gemcitabine + NC-6004 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | Completed | USA | ROU | POL | ITA | BGR | 0 |
| NCT02393248 | Phase Ib/II | Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Terminated | USA | DNK | 0 |
| NCT02452970 | Phase II | RRx-001 Cisplatin + Gemcitabine | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) | Terminated | USA | 0 |
| NCT02479178 | Phase II | BIND-014 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) | Terminated | USA | 1 |
| NCT02508467 | Phase I | Fisogatinib | A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | CHE | 5 |
| NCT02520141 | Phase II | Ramucirumab | Ramucirumab for Advanced Pre-treated Biliary Cancers | Completed | USA | 0 |
| NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Active, not recruiting | 0 | |
| NCT02632305 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel | A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) | Active, not recruiting | CAN | 0 |
| NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
| NCT02711553 | Phase II | Ramucirumab Merestinib Cisplatin + Gemcitabine | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | Active, not recruiting | USA | TUR | SWE | HUN | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUT | AUS | ARG | 4 |
| NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Terminated | USA | FRA | ESP | DNK | 0 |
| NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT02856568 | Phase I | Cisplatin + Gemcitabine + Ricolinostat | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma | Withdrawn | USA | 0 |
| NCT02924376 | Phase II | Pemigatinib | Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | BEL | 4 |
| NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
| NCT02982720 | Phase II | Peginterferon alfa-2b + Pembrolizumab | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | Terminated | USA | 0 |
| NCT02989857 | Phase III | Ivosidenib | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) | Completed | USA | ITA | GBR | FRA | ESP | 1 |
| NCT03093870 | Phase II | Capecitabine + Varlitinib Capecitabine | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer | Completed | USA | POL | HUN | ESP | AUS | 6 |
| NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Completed | USA | 0 |
| NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Completed | USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | BEL | AUS | 2 |
| NCT03132792 | Phase I | AFPc332T | AFPc332T in Advanced HCC | Active, not recruiting | USA | GBR | FRA | ESP | 0 |
| NCT03144661 | Phase I | INCB062079 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | Terminated | USA | BEL | 0 |
| NCT03201458 | Phase II | Atezolizumab Atezolizumab + Cobimetinib | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
| NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
| NCT03212274 | Phase II | Olaparib | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | 0 |
| NCT03230318 | Phase II | Derazantinib | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) | Completed | USA | ITA | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BEL | 1 |
| NCT03250273 | Phase II | Entinostat + Nivolumab | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | Completed | USA | 0 |
| NCT03257761 | Phase I | Durvalumab + Guadecitabine | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | Active, not recruiting | USA | 0 |
| NCT03267940 | Phase I | Cisplatin + Gemcitabine Atezolizumab + Cisplatin + Gemcitabine + PEGPH20 Cisplatin + Gemcitabine + PEGPH20 | Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | Terminated | USA | 2 |
| NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT03339843 | Phase II | Abemaciclib | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) | Completed | FRA | BEL | 0 |
| NCT03368963 | Phase Ib/II | Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Active, not recruiting | USA | 0 |
| NCT03377179 | Phase II | ABC294640 | A Study of ABC294640 in the Treatment of Patients With Advanced Cholangiocarcinoma | Completed | USA | 0 |
| NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
| NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
| NCT03656536 | Phase III | Pemigatinib Cisplatin + Gemcitabine | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302) | Terminated | USA | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BEL | AUT | 2 |
| NCT03704480 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) | Active, not recruiting | FRA | 0 |
| NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
| NCT03773302 | Phase III | Cisplatin + Gemcitabine Infigratinib | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 6 |
| NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | AUS | ARG | 6 |
| NCT03872947 | Phase I | Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | Active, not recruiting | USA | FRA | 0 |
| NCT03878095 | Phase II | Ceralasertib + Olaparib | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | Active, not recruiting | USA | 0 |
| NCT03907852 | Phase Ib/II | Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | CAN | 0 |
| NCT03943004 | Phase I | DFP-14927 | Trial of DFP-14927 in Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT04003636 | Phase III | Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) | Completed | USA | TUR | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
| NCT04003896 | Phase II | Abemaciclib | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy | Terminated | USA | 0 |
| NCT04034238 | Phase I | LMB-100 + Tofacitinib | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | Completed | USA | 0 |
| NCT04057365 | Phase II | DKN-01 + Nivolumab | A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) | Terminated | USA | 0 |
| NCT04068194 | Phase Ib/II | Avelumab Avelumab + Peposertib | Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | Active, not recruiting | USA | 0 |
| NCT04088188 | Phase I | Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | Terminated | USA | 0 |
| NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Completed | USA | FRA | ESP | DEU | BEL | 3 |
| NCT04149691 | Phase I | CPL304110 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Unknown status | POL | 0 |
| NCT04157985 | Phase III | Nivolumab Ipilimumab Cemiplimab Pembrolizumab Atezolizumab | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | Completed | USA | 0 |
| NCT04175912 | Phase II | Carboplatin + MLN4924 + Paclitaxel MLN4924 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | Active, not recruiting | USA | 0 |
| NCT04233567 | Phase II | Infigratinib | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | Completed | USA | 0 |
| NCT04294576 | Phase I | BJ-001 + Pembrolizumab BJ-001 | Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) | Unknown status | USA | 0 |
| NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) | Terminated | USA | CAN | 1 |
| NCT04306367 | Phase II | Olaparib + Pembrolizumab | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | Completed | USA | 0 |
| NCT04396821 | Phase I | TST001 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
| NCT04430738 | Phase Ib/II | Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Active, not recruiting | USA | 1 |
| NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
| NCT04507503 | Expanded access | Futibatinib | Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | Approved for marketing | USA | 0 |
| NCT04521686 | Phase I | LY3410738 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | FRA | ESP | AUS | 5 |
| NCT04565275 | Phase Ib/II | ICP-192 | A Study of ICP-192 in Patients With Advanced Solid Tumors | Unknown status | USA | AUS | 0 |
| NCT04641871 | Phase I | Sym021 + Sym023 Sym021 + Sym022 | Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies | Completed | USA | FRA | ESP | CAN | 0 |
| NCT04645160 | Phase Ib/II | Tivozanib | Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma | Recruiting | USA | 0 |
| NCT04648319 | Phase II | Nivolumab | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | Terminated | LUX | LBN | BEL | 0 |
| NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Completed | USA | CAN | 0 |
| NCT04676633 | Phase I | Cotsiranib | Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy | Completed | USA | 0 |
| NCT04677504 | Phase II | Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | Completed | USA | TUR | POL | ITA | GBR | ESP | 7 |
| NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
| NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Terminated | USA | ISR | GBR | CAN | 0 |
| NCT04781192 | Phase Ib/II | Durvalumab + Regorafenib | The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers | Active, not recruiting | USA | 0 |
| NCT04914286 | Phase Ib/II | GFH018 + Toripalimab-tpzi | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Completed | AUS | 1 |
| NCT04919642 | Phase II | Tinengotinib | Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma | Completed | USA | 0 |
| NCT04972981 | Phase I | ADCT-901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Completed | USA | GBR | ESP | 0 |
| NCT04973163 | Phase I | BI 1823911 + Midazolam BI 1701963 + BI 1823911 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Active, not recruiting | USA | GBR | ESP | BEL | 0 |
| NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Terminated | USA | 0 |
| NCT05007106 | Phase II | MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | Completed | USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN | 5 |
| NCT05176665 | Phase Ib/II | EMB-01 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | Recruiting | USA | 1 |
| NCT05194072 | Phase I | SGN-B7H4V | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Terminated | USA | GBR | ESP | DEU | CAN | 0 |
| NCT05211323 | Phase II | Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine | A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer | Active, not recruiting | USA | 0 |
| NCT05221320 | Phase II | Hydroxychloroquine + Ulixertinib | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Terminated | USA | 0 |
| NCT05228015 | Phase I | IK-930 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors | Terminated | USA | GBR | AUS | 0 |
| NCT05244551 | Phase I | ABSK061 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT05275478 | Phase Ib/II | TNG908 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Active, not recruiting | USA | FRA | 0 |
| NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
| NCT05346484 | Phase I | CF33-hNIS + Pembrolizumab CF33-hNIS CF33-hNIS + Fluorouracil + Leucovorin + Oxaliplatin | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST) | Terminated | USA | AUS | 0 |
| NCT05411133 | Phase I | ARB202 + Atezolizumab ARB202 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | Completed | AUS | 1 |
| NCT05506943 | Phase II | Paclitaxel CTX-009 + Paclitaxel | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers | Active, not recruiting | USA | 0 |
| NCT05510427 | Phase I | Atezolizumab + Bevacizumab + Infigratinib | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | Withdrawn | 0 | |
| NCT05512377 | Phase II | BI 907828 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Completed | USA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 7 |
| NCT05568680 | Phase I | SynKIR-110 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Recruiting | USA | 0 |
| NCT05615818 | Phase III | Niraparib Zanidatamab Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib | Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) | Recruiting | GBR | FRA | BEL | 0 |
| NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Withdrawn | USA | 0 |
| NCT05694715 | Phase I | Irinotecan + Niraparib | Combination Therapy in Cancers With Mutations in DNA Repair Genes | Recruiting | USA | 0 |
| NCT05712356 | Phase II | CEND-1 + Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Paclitaxel Docetaxel CEND-1 + Docetaxel CEND-1 + Paclitaxel | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER) | Active, not recruiting | USA | 0 |
| NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Active, not recruiting | USA | ESP | BEL | 0 |
| NCT05727176 | Phase II | Futibatinib | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4) | Recruiting | USA | POL | ITA | ESP | CAN | BRA | AUS | ARG | 5 |
| NCT05733598 | Phase II | Durvalumab + RP2 Atezolizumab + Bevacizumab + RP2 RP2 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Recruiting | USA | 0 |
| NCT05791448 | Phase I | AU409 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | Recruiting | USA | 0 |
| NCT05848843 | Phase I | Adagrasib + Durvalumab | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Withdrawn | USA | 0 |
| NCT05862324 | Phase Ib/II | TAC01-CLDN18.2 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) | Active, not recruiting | USA | CAN | 0 |
| NCT05876754 | Phase III | Ivosidenib | An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe) | Recruiting | SWE | ROU | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 3 |
| NCT05921760 | Phase Ib/II | Ipilimumab + Ivosidenib + Nivolumab | Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | Terminated | USA | GBR | 0 |
| NCT05948475 | Phase III | Tinengotinib | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308) | Recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | 3 |
| NCT05958199 | Phase I | NPX267 | Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 | Suspended | USA | 0 |
| NCT05967182 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
| NCT06178445 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab + Trastuzumab | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC) | Recruiting | DEU | 0 |
| NCT06178588 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | Active, not recruiting | USA | 0 |
| NCT06233942 | Phase I | BG-C9074 BG-C9074 + Tislelizumab Bevacizumab + BG-C9074 | Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | Recruiting | USA | BRA | AUS | 1 |
| NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
| NCT06282575 | Phase III | Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + Zanidatamab Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + Zanidatamab Cisplatin + Gemcitabine + Zanidatamab | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Recruiting | USA | TUR | SWE | ROU | ITA | ISR | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | ARG | 9 |
| NCT06302621 | Phase I | Afatinib + Pemigatinib | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
| NCT06341764 | Phase II | Cisplatin + Durvalumab + Gemcitabine + Tremelimumab | Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma | Recruiting | ITA | 0 |
| NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06400485 | Phase I | AMT-676 | AMT-676 in Patients With Advanced Solid Tumors | Recruiting | AUS | 2 |
| NCT06439485 | Phase II | Atezolizumab + Bevacizumab + Pemigatinib | Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | Recruiting | USA | 0 |
| NCT06440993 | Phase II | Cisplatin + Durvalumab + Gemcitabine | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma | Recruiting | DEU | 0 |
| NCT06441747 | Phase II | Durvalumab + Olaparib | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | Recruiting | AUS | 0 |
| NCT06501625 | Phase Ib/II | Cisplatin + Durvalumab + Gemcitabine + Ivosidenib | Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Recruiting | USA | FRA | ESP | DEU | CAN | BRA | AUS | 2 |
| NCT06597721 | Phase I | AMT-754 | AMT-754 in Patients With Selected Advanced Solid Tumours | Recruiting | USA | AUS | 0 |
| NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Active, not recruiting | BRA | 0 |
| NCT06690281 | Phase II | Cyclophosphamide + Fludarabine Aldesleukin + Autologous KRAS mutant TCR-transduced PBLs | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | Withdrawn | USA | 0 |
| NCT06723236 | Phase I | MGC028 | A Study of MGC028 in Participants with Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT06725758 | Phase Ib/II | ODM-212 | A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours (TEADES) | Recruiting | GBR | 0 |
| NCT06789848 | Phase II | AK117 + Cadonilimab | Ligufalimab and Cadonilimab in Advanced Liver Cancers | Recruiting | USA | 0 |
| NCT06864169 | Phase II | Raludotatug deruxtecan | A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) (REJOICE-GI01) | Active, not recruiting | USA | FRA | ESP | CHE | CAN | ARG | 4 |
| NCT06940349 | Phase Ib/II | Palbociclib + Sunitinib | Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors (COPS-01) | Recruiting | ISR | 0 |
| NCT07036380 | Phase II | Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine + MP0317 | MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (TACTIC) | Recruiting | FRA | 0 |
| NCT07070232 | Phase Ib/II | BNT327 + YL202 YL202 Itraconazole + YL202 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | BEL | AUS | 0 |
| NCT07107750 | Phase I | CA-4948 + Cisplatin + Durvalumab + Gemcitabine | CA-4948 in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | Not yet recruiting | USA | 0 |
| NCT07124117 | Phase Ib/II | OBI-902 | A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT07146646 | Phase II | Oxaliplatin + Trifluridine-tipiracil hydrochloride | Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer | Recruiting | USA | 0 |
| NCT07148128 | Phase Ib/II | WEF-001 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | Recruiting | USA | GBR | CAN | 0 |
| NCT07163325 | Phase I | EP102 | EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | Recruiting | NLD | ESP | CZE | BEL | 0 |
| NCT07213791 | Phase I | LY4337713 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT) | Recruiting | USA | NLD | DEU | 0 |
| NCT07221253 | Phase III | Cisplatin + Durvalumab + Gemcitabine AZD2936 + Cisplatin + Gemcitabine | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (AB02) | Recruiting | USA | TUR | POL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 6 |
| NCT07382544 | Phase I | MRTX1719 + Olaparib | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss | Recruiting | USA | 0 |